Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) noticed its shares barely moving in the first hour Monday, as the late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, in Lisbon, Portugal.
Among the seven presentations on SUL-DUR, the Waltham, Mass.-based Entasis will deliver two oral presentations and three posters on the topline results from its ATTACK trial—a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter and the first trial to evaluate an investigational agent targeting a specific drug-resistant Gram-negative pathogen.
Said CEO Manos Perros, “We are pleased to share data from our Phase 3 trial at ECCMID. SUL-DUR is the first investigational drug to demonstrate efficacy in a 28-day all-cause mortality trial focused on carbapenem-resistant Acinetobacter, an “Urgent” threat as designated by the CDC.”
The oral presentations are set to begin this coming Sunday
ETTX shares were fairly static to $1.90.
